Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Approves Companion Diagnostic For Obesity Drug

Executive Summary

The US FDA has given thumbs-up to a genetic test from PreventionGenetics, the first agency-approved class II molecular companion diagnostic that looks for genetic deficiencies associated with obesity.

You may also be interested in...

Class I Recall For BD Intraosseous Infusion System

The US FDA has labelled a recall of Becton Dickinson intraosseous needle set kits, manual driver kits, and powered drivers as class I, its most severe designation. 

US CDC Teams Up With ACLA To Expand Monkeypox Testing

The US CDC and major laboratories across the country are working together to scale up testing capacity for monkeypox, especially now that it has been declared a public health emergency.

Class I Recall For Haimen Shengbang Viral Sampling Containers

The US FDA has designated a recall of Haimen Shengbang Laboratory Equipment Co. viral transport media containers as class I, the agency’s most serious designation.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts